

> SCIENCES DE LA VIE ET DE LA TERRE

Mettre en œuvre son enseignement dans la classe

Thème 3 : le corps humain et la santé

Une association entre l'usage de cannabis et le développement de psychoses a été suspectée depuis longtemps.

Références

Livres et reviews utilisés pour construire l'analyse

Bramon et al., 2005, Is the P300 wave an endophenotype for schizophrenia ? A meta-analysis and a family study, *NeuroImage* 27, 960 – 968.

Madras, Kuhar, 2014, *The effects of drug abuse on the human nervous system*, Elsevier.

Malchow et al., 2013, Cannabis abuse and brain morphology in schizophrenia : a review of the available evidence, *Aur Arch Psychiatry Clin Neurosci* 263 :3-13.

Sewel et al., 2010, Behavioral, cognitive and psychophysiological effects of cannabinoids : relevance to psychosis and schizophrenia, *Revista Brasileira de Psiquiatria*, vol 32, Suppl I.

Solowij et al., 2006, Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia ?, *J Psychiatry Neurosci* 2007;32(1) : 30-52.

Études utilisées comme références

Ames, F., 1958. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. *J. Ment. Sci.* 104, 972–999.

Andreasen, N.C., Nopoulos, P., O'Leary, D.S., Miller, D.D., Wassink, T., Flaum, M., 1999. Defining the phenotype of schizophrenia : cognitive dysmetria and its neural mechanisms. *Biol. Psychiatry* 46, 908–920.

Andreasson, S., Allebeck, P., Engstrom, A., Rydberg, U., 1987. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet* 2, 1483–1486.

Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., Moffitt, T.E., 2002. Cannabis use in adolescence and risk for adult psychosis : longitudinal prospective study. *BMJ* 325, 1212–1213.

Bangalore, S.S., Prasad, K.M., Montrose, D.M., Goradia, D.D., Diwadkar, V.A., Keshavan, M.S., 2008. Cannabis use and brain structural alterations in first episode schizophrenia—a region of interest, voxel based morphometric study. *Schizophr. Res.* 99, 1–6.

Berghuis, P., Dobszay, M.B., Wang, X., Spano, S., Ledda, F., Sousa, K.M., Schulte, G., Ernfors, P., Mackie, K., Paratcha, G., Hurd, Y.L., Harkany, T., 2005. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. *Proc. Natl. Acad. Sci. U.S.A*

102, 19115–19120.

Berghuis, P., Rajniecek, A.M., Morozov, Y.M., Ross, R.A., Mulder, J., Urban, G.M., Monory, K., Marsicano, G., Matteoli, M., Canty, A., Irving, A.J., Katona, I., Yanagawa, Y., Rakic, P., Lutz, B., Mackie, K., Harkany, T., 2007. Hardwiring the brain : endocannabinoids shape neuronal connectivity. *Science* 316, 1212–1216.

Block, R.I., O’Leary, D.S., Ehrhardt, J.C., Augustinack, J.C., Ghoneim, M.M., Arndt, S., Hall, J.A., 2000. Effects of frequent marijuana use on brain tissue volume and composition. *Neuroreport* 11, 491–496.

Braff, D.L., Light, G.A., 2004. Preattentive and attentional cognitive deficits as targets for treating schizophrenia. *Psychopharmacology (Berl.)* 174, 75–85.

Bramon, E., Rabe-Hesketh, S., Sham, P., Murray, R.M., Frangou, S., 2004. Meta-analysis of the P300 and P50 waveforms in schizophrenia. *Schizophr. Res.* 70, 315–329.

Bramon, E., McDonald, C., Croft, R.J., Landau, S., Filbey, F., Gruzelier, J.H., Sham, P.C., Frangou, S., Murray, R.M., 2005. Is the P300 wave an endophenotype for schizophrenia ? A meta-analysis and a family study. *NeuroImage* 27, 960–968.

Brook, M., 1984. Psychosis after cannabis abuse. *BMJ* 288, 1381 (Clinical research ed.).

Broyd, 2016, Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users (Neural Plasticity).

Butovsky, E., Juknat, A., Goncharov, I., Elbaz, J., Eilam, R., Zangen, A., Vogel, Z., 2005. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-tetrahydrocannabinol. *J. Neurochem.* 93, 802–811.

Cahn, W., Hulshoff Pol, H.E., Caspers, E., van Haren, N.E., Schnack, H.G., Kahn, R.S., 2004. Cannabis and brain morphology in recent-onset schizophrenia. *Schizophr. Res.* 67, 305–307.

Campbell, A.M., Evans, M., Thomson, J.L., Williams, M.J., 1971. Cerebral atrophy in young cannabis smokers. *Lancet* 2, 1219–1224.

Chan, G.C., Hinds, T.R., Impey, S., Storm, D.R., 1998. Hippocampal neurotoxicity of delta9-tetrahydrocannabinol. *J. Neurosci.* 18, 5322–5332.

Chopra, G.S., Smith, J.W., 1974. Psychotic reactions following cannabis use in East Indians. *Arch. Gen. Psychiatry* 30, 24–27.

Conrad, D.G., Elsmore, T.F., Sodetz, F.J., 1972. 9-tetrahydrocannabinol : dose-related effects on timing behavior in chimpanzee. *Science* 175, 547–550 New York, N.Y.

Cohen, J., Morrison, S., Greenberg, J., Saidinejad, M., 2012. Clinical presentation of intoxication due to synthetic cannabinoids. *Pediatrics*.

D’Souza, D.C., 2007. Cannabinoids and psychosis. *Int. Rev. Neurobiol.* 78, 289–326.

D’Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.T., Braley, G., Gueorguieva, R., Krystal, J.H., 2004. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals : implications for psychosis. *Neuropsychopharmacology* 29, 1558–1572.

D’Souza, D.C., Abi-Saab, W.M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T.B., Krystal, J.H., 2005. Delta-9-tetrahydrocannabinol effects in schizophrenia : implications for cognition, psychosis, and addiction. *Biol. Psychiatry* 57, 594–608.

- D'Souza, D.C., Pittman, B., Perry, E., Simen, A., 2008a. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. *Psychopharmacology (Berl.)*.
- D'Souza, D.C., Ranganathan, M., Braley, G., Gueorguieva, R., Zimolo, Z., Cooper, T., Perry, E., Krystal, J., 2008b. Blunted psychotomimetic and amnesic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. *Neuropsychopharmacology* 33, 2505–2516.
- D'Souza, D.C., Sewell, R.A., Ranganathan, M., 2009. Cannabis and psychosis/schizophrenia : human studies. *Eur. Arch. Psychiatry Clin. Neurosci.* 259, 413–431.
- D'Souza, D.C., Fridberg, D.J., Skosnik, P.D., Williams, A., Roach, B., Singh, N., Carbuto, M., Elander, J., Schnakenberg, A., Pittman, B., Sewell, R.A., Ranganathan, M., Mathalon, D., 2012. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous delta(9)-THC in humans. *Neuropsychopharmacology*.
- Davalos, D.B., Kisley, M.A., Ross, R.G., 2003. Effects of interval duration on temporal processing in schizophrenia. *Brain Cogn.* 52, 295–301.
- Dekker, N., Schmitz, N., Peters, B.D., van Amelsvoort, T.A., Linszen, D.H., de Haan, L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. *Psychiatry Res.* 181, 51–56.
- Derkinderen, P., Valjent, E., Toutant, M., Corvol, J.C., Enslin, H., Ledent, C., Trzaskos, J., Caboche, J., Girault, J.A., 2003. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. *J. Neurosci.* 23, 2371–2382.
- Dissanayake, D.W., Zachariou, M., Marsden, C.A., Mason, R., 2008. Auditory gating in rat hippocampus and medial prefrontal cortex : effect of the cannabinoid agonist WIN55,212-2. *Neuropharmacology* 55, 1397–1404.
- Eggan, S.M., Lewis, D.A., 2007. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex : a regional and laminar analysis. *Cereb. Cortex* 17, 175–191.
- Emrich, H.M., Weber, M.M., Wendl, A., Zihl, J., von Meyer, L., Hanisch, W., 1991. Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment. *Pharmacol. Biochem. Behav.* 40, 689–690.
- Frank, M.J., Moustafa, A.A., Haughey, H.M., Curran, T., Hutchison, K.E., 2007. Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. *Proc. Natl. Acad. Sci. U.S.A.* 104, 16311–16316.
- Garcia-Gil, L., Romero, J., Ramos, J.A., Fernandez-Ruiz, J.J., 1999. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. *Drug Alcohol Depend.* 55, 127–136.
- Galve-Roperh, I., Palazuelos, J., Aguado, T., Guzman, M., 2009. The endocannabinoid system and the regulation of neural development : potential implications in psychiatric disorders. *Eur. Arch. Psychiatry Clin. Neurosci.* 259, 371–382.
- Gobbi, G., Bambico, F.R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M.G., Debonnel, G., Duranti, A., Tontini, A., Tarzia, G., Mor, M., Trezza, V., Goldberg, S.R., Cuomo, V., Piomelli, D., 2005. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proc. Natl. Acad. Sci. U.S.A.* 102, 18620–18625.
- Goldschmidt, L., Day, N.L., Richardson, G.A., 2000. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol. Teratol.* 22, 325–336.
- Grossman, W., 1969. Adverse reactions associated with cannabis products in India. *Ann. Intern. Med.* 70, 529–533.

- Grunwald, T., Boutros, N.N., Pezer, N., von Oertzen, J., Fernandez, G., Schaller, C., Elger, C.E., 2003. Neuronal substrates of sensory gating within the human brain. *Biol. Psychiatry* 53, 511–519.
- Halikas, J., Weller, R., Morse, C., 1982. Effects of regular marijuana use on sexual performance. *J. Psychoactive Drugs* 14, 59–70.
- Hall, W., Solowij, N., 1998. Adverse effects of cannabis. *Lancet* 352, 1611–1616.
- Han, C.J., Robinson, J.K., 2001. Cannabinoid modulation of time estimation in the rat. *Behav. Neurosci.* 115, 243–246.
- Harkany, T., Guzman, M., Galve-Roperh, I., Berghuis, P., Devi, L.A., Mackie, K., 2007. The emerging functions of endocannabinoid signaling during CNS development. *Trends Pharmacol. Sci.* 28, 83–92.
- Hart, C.L., van Gorp, W., Haney, M., Foltin, R.W., Fischman, M.W., 2001. Effects of acute smoked marijuana on complex cognitive performance. *Neuro-psychopharmacology* 25, 757–765.
- Heinrichs, R.W., Zakzanis, K.K., 1998. Neurocognitive deficit in schizophrenia : a quantitative review of the evidence. *Neuropsychology* 12, 426–445.
- Heishman, S.J., Huestis, M.A., Henningfield, J.E., Cone, E.J., 1990. Acute and residual effects of marijuana : profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol. Biochem. Behav.* 37, 561–565.
- Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Fananas, L., Drukker, M., Ramaekers, J.G., van Os, J., 2006. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. *Neuropsychopharmacology* 31, 2748–2757.
- Hicks, R.E., Gualtieri, C.T., Mayo Jr., J.P., Perez-Reyes, M., 1984. Cannabis, atropine, and temporal information processing. *Neuropsychobiology* 12, 229–237.
- Hooker, W.D., Jones, R.T., 1987. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. *Psychopharmacology* 91, 20–24.
- Isbell, H., Jasinski, D.R., 1969. A comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. *Psychopharmacologia* 14, 115–123.
- Jager, G., Van Hell, H.H., DeWin, M.M., Kahn, R.S., Van Den Brink, W., Van Ree, J.M., Ramsey, N.F., 2007. Effects of frequent cannabis use on hippocampal activity during an associative memory task. *Eur. Neuropsychopharmacol.* 17, 289–297.
- James, A., Hough, M., James, S., Winmill, L., Burge, L., Nijhawan, S., Matthews, P.M., Zarei, M., 2011. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). *Schizophr. Res.* 128, 91–97.
- Jeon, Y.W., Polich, J., 2003. Meta-analysis of P300 and schizophrenia : patients, paradigms, and practical implications. *Psychophysiology* 40, 684–701.
- Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S.P., Bai, G., Zhang, X., 2005. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. *J. Clin. Invest.* 115, 3104–3116.
- Jutras-Aswad, D., DiNieri, J.A., Harkany, T., Hurd, Y.L., 2009. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. *Eur. Arch. Psychiatry Clin. Neurosci.* 259, 395–412.

- Keeler, M.H., Moore, E., 1974. Paranoid reactions while using marijuana. *Dis. Nerv. Syst.* 35, 535–536.
- Kempel, P., Lampe, K., Parnefjord, R., Hennig, J., Kunert, H.J., 2003. Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. *Neuropsychobiology* 48, 95–101.
- Kolansky, H., Moore, W.T., 1971. Effects of marijuana on adolescents and young adults. *J Psychiatr. Nurs. Ment. Health Serv.* 9, 9–16.
- Kuepper, R., van Os, J., Lieb, R., Wittchen, H.U., Hofler, M., Henquet, C., 2011b. Continued cannabis use and risk of incidence and persistence of psychotic symptoms : 10 year follow-up cohort study. *BMJ* 342, d738.
- Kumra, S., Robinson, P., Tambyraja, R., Jensen, D., Schimunek, C., Hourri, A., Reis, T., Lim, K., 2012. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. *J. Am. Acad. Child Adolesc. Psychiatry* 51, 171–180.
- Landfield, P.W., Cadwallader, L.B., Vinsant, S., 1988. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol : possible mediation by glucocorticoid systems. *Brain Res.* 443, 47–62.
- Lawston, J., Borella, A., Robinson, J.K., Whitaker-Azmitia, P.M., 2000. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. *Brain Res.* 877, 407–410.
- Leweke, M., Kampmann, C., Radwan, M., Dietrich, D.E., Johannes, S., Emrich, H.M., Munte, T.F., 1998. The effects of tetrahydrocannabinol on the recognition of emotionally charged words : an analysis using event-related brain potentials. *Neuropsychobiology* 37, 104–111.
- Leweke, F.M., Schneider, U., Radwan, M., Schmidt, E., Emrich, H.M., 2000. Different effects of nabilone and cannabidiol on binocular depth inversion in man. *Pharmacol. Biochem. Behav.* 66, 175–181.
- Lichtman, A.H., Varvel, S.A., Martin, B.R., 2002. Endocannabinoids in cognition and dependence. *Prostaglandins Leukot. Essent. Fatty Acids* 66, 269–285.
- Luntz-Leybman, V., Bickford, P.C., Freedman, R., 1992. Cholinergic gating of response to auditory stimuli in rat hippocampus. *Brain Res.* 587, 130–136.
- Maj, P.F., Collu, M., Fadda, P., Cattaneo, A., Racagni, G., Riva, M.A., 2007. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist [R]-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone. *Eur. J. Neurosci.* 25, 3305–3311.
- Manrique-Garcia, 2011. Cannabis, schizophrenia and other non-affective psychoses : 35 years of follow-up of a population-based cohort, *Psychological Medicine*, 30 août 2011.
- Marks, D.F., MacAvoy, M.G., 1989. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. *Psychopharmacology* 99, 397–401.
- Mata, I., Perez-Iglesias, R., Roiz-Santianez, R., Tordesillas-Gutierrez, D., Pazos, A., Gutierrez, A., Vazquez-Barquero, J.L., Crespo-Facorro, B., 2010. Gyrfication brain abnormalities associated with adolescence and early-adulthood cannabis use. *Brain Res.* 1317, 297–304.

Marshall, C., 1897. The active principle of Indian hemp ; a preliminary communication. *Lancet* 1, 235–238.

Mathew, R.J., Wilson, W.H., Turkington, T.G., Coleman, R.E., 1998. Cerebellar activity and disturbed time sense after THC. *Brain Res.* 797, 183–189.

Matochik, J.A., Eldreth, D.A., Cadet, J.L., Bolla, K.I., 2005. Altered brain tissue composition in heavy marijuana users. *Drug Alcohol Depend.* 77, 23–30.

Mayor's Committee on Marijuana, 1944. The LaGuardia Committee Report : The Marijuana Problem in the City of New York. The New York Academy of Medicine, New York.

McClure, G.Y., McMillan, D.E., 1997. Effects of drugs on response duration differentiation. VI: differential effects under differential reinforcement of low rates of responding schedules. *J. Pharmacol. Exp. Ther.* 281, 1368–1380.

McDonald, J., Schleifer, L., Richards, J.B., de Wit, H., 2003. Effects of THC on behavioral measures of impulsivity in humans. *Neuropsychopharmacology* 28, 1356–1365.

Medina, K.L., Hanson, K.L., Schweinsburg, A.D., Cohen-Zion, M., Nagel, B.J., Tapert, S.F., 2007a. Neuropsychological functioning in adolescent marijuana users : subtle deficits detectable after a month of abstinence. *J. Int. Neuropsychol. Soc.* 13, 807–820.

Medina, K.L., Nagel, B.J., Park, A., McQueeny, T., Tapert, S.F., 2007b. Depressive symptoms in adolescents : associations with white matter volume and marijuana use. *J. Child Psychol. Psychiatry* 48, 592–600.

Miller, L.L., McFarland, D., Cornett, T.L., Brightwell, D., 1977. Marijuana and memory impairment : effect on free recall and recognition memory. *Pharmacol. Biochem. Behav.* 7, 99–103.

Millman, R.B., Sbriglio, R., 1986. Patterns of use and psychopathology in chronic marijuana users. *Psychiatr. Clin. North Am.* 9, 533–545.

Molina-Holgado, F., Alvarez, F.J., Gonzalez, I., Antonio, M.T., Leret, M.L., 1997. Maternal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) alters indolamine levels and turnover in adult male and female rat brain regions. *Brain Res. Bull.* 43, 173–178.

Moreau, J., 1973. Hashish and Mental Illness. Raven, New York.

Morrison, P.D., Zois, V., McKeown, D.A., Lee, T.D., Holt, D.W., Powell, J.F., Kapur, S., Murray, R.M., 2009. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. *Psychol. Med.* 39, 1607–1616.

Mulder, J., Aguado, T., Keimpema, E., Barabas, K., Ballester Rosado, C.J., Nguyen, L., Monory, K., Marsicano, G., Di Marzo, V., Hurd, Y.L., Guillemot, F., Mackie, K., Lutz, B., Guzman, M., Lu, H.C., Galve-Roperh, I., Harkany, T., 2008. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. *Proc. Natl. Acad. Sci. U.S.A.* 105, 8760–8765.

Oudin, M.J., Gajendra, S., Williams, G., Hobbs, C., Lalli, G., Doherty, P., 2011. Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain. *J. Neurosci.* 31, 4000–4011.

Patrick, G., Straumanis, J.J., Struve, F.A., Fitz-Gerald, M.J., Leavitt, J., Manno, J.E., 1999. Reduced P50 auditory gating response in psychiatrically normal chronic marijuana users : a pilot study. *Biol. Psychiatry* 45, 1307–1312.

Patrick, G., Struve, F.A., 2000. Reduction of auditory P50 gating response in marijuana users : further supporting data. *Clin. Electroencephalogr.* 31, 88–93.

- Patterson, J.V., Hetrick, W.P., Boutros, N.N., Jin, Y., Sandman, C., Stern, H., Potkin, S., Bunney Jr., W.E., 2008. P50 sensory gating ratios in schizophrenics and controls : a review and data analysis. *Psychiatry Res.* 158, 226–247.
- Peters, B.D., de Haan, L., Vlieger, E.J., Majoie, C.B., den Heeten, G.J., Linszen, D.H., 2009. Recent-onset schizophrenia and adolescent cannabis use : MRI evidence for structural hyperconnectivity ? *Psycho-pharmacol. Bull.* 42, 75–88.
- Potter, D., Summerfelt, A., Gold, J., Buchanan, R.W., 2006. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. *Schizophr. Bull.* 32, 692–700.
- Psychoyos, D., Hungund, B., Cooper, T., Finnell, R.H., 2008. A cannabinoid analogue of delta-9-tetrahydrocannabinol disrupts neural development in chick. *Birth Defects Res. B Dev. Reprod. Toxicol.* 83, 477–488.
- Psychoyos, D., Vinod, K.Y., Cao, J., Xie, S., Hyson, R.L., Wlodarczyk, B., He, W., Cooper, T.B., Hungund, B.L., Finnell, R.H., 2012. Cannabinoid receptor 1 signaling in embryo neurodevelopment. *Birth Defects Res. B Dev. Reprod. Toxicol.*
- Rais, M., Cahn, W., Van Haren, N., Schnack, H., Caspers, E., Hulshoff Pol, H., Kahn, R., 2008. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. *Am. J. Psychiatry* 165, 490–496.
- Ranganathan, M., D'Souza, D.C., 2006. The acute effects of cannabinoids on memory in humans : a review. *Psychopharmacology (Berl.)* 188, 425–444.
- Rapoport, J.L., Addington, A.M., Frangou, S., Psych, M.R., 2005. The neurodevelopmental model of schizophrenia : update 2005. *Mol. Psychiatry* 10, 434–449.
- Renault, P.F., Schuster, C.R., Freedman, D.X., Sikic, B., de Mello, D.N., 1974. Repeat administration of marijuana smoke to humans. *Arch. Gen. Psychiatry* 31, 95–102.
- Rubino, T., Vigano, D., Premoli, F., Castiglioni, C., Bianchessi, S., Zippel, R., Parolaro, D., 2006. Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance : a role for RAS-ERK cascade. *Mol. Neurobiol.* 33, 199–213.
- Rubino, T., Realini, N., Braidà, D., Guidi, S., Capurro, V., Vigano, D., Guidali, C., Pinter, M., Sala, M., Bartesaghi, R., Parolaro, D., 2009. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. *Hippocampus* 19, 763–772.
- Medina et al., 2007a ; Matochik et al., 2005 ; Medina et al., 2007c ; Cousijn et al., 2012 ; Solowij et al., 2011 ; Mata et al., 2010.
- Semple, D.M., Ramsden, F., McIntosh, A.M., 2003. Reduced binocular depth inversion in regular cannabis users. *Pharmacol. Biochem. Behav.* 75, 789–793.
- Siler, J.F., Sheep, W.L., Bates, L.B., Clark, G.F., Cook, G.W., Smith, W.A., 1933. Marijuana smoking in Panama. *Mil. Surg.* 73, 269–280.
- Schulze, G.E., McMillan, D.E., Bailey, J.R., Scallet, A., Ali, S.F., Slikker Jr., W., Paule, M.G., 1988. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. *J. Pharmacol. Exp. Ther.* 245, 178–186.
- Sewell, A., D'Souza, D.C., 3 April 2011. Impairment of Time Estimation and Reproduction by Δ^9 -THC.
- Smith, D.E., 1968. Acute and chronic toxicity of marijuana. *J. Psychedelic Drugs* 2, 37–47.
- Solowij, N., 1995. Do cognitive impairments recover following cessation of cannabis use ? *Life Sci.* 56, 2119–2126.

- Solowij, N., Michie, P.T., Fox, A.M., 1991. Effects of long-term cannabis use on selective attention : an event-related potential study. *Pharmacol. Biochem. Behav.* 40, 683–688.
- Solowij, N., Yucel, M., Respondek, C., Whittle, S., Lindsay, E., Pantelis, C., Lubman, D.I., 2011. Cerebellar white-matter changes in cannabis users with and without schizophrenia. *Psychol. Med.* 41, 2349–2359.
- Stone, J.M., Morrison, P.D., Nottage, J., Bhattacharyya, S., Feilding, A., McGuire, P.K., 2010. Delta-9-tetrahydro-cannabinol disruption of time perception and of self-timed actions. *Pharmacopsychiatry* 43, 236–237.
- Spencer, D.J., 1971. Cannabis-induced psychosis. *Int. J. Addict.* 6, 323–326.
- Szeszko, P.R., Robinson, D.G., Sevy, S., Kumra, S., Rupp, C.I., Betensky, J.D., Lencz, T., Ashtari, M., Kane, J.M., Malhotra, A.K., Gunduz-Bruce, H., Napoli-tano, B., Bilder, R.M., 2007. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. *Br. J. Psychiatry* 190, 230–236.
- Talbott, J.A., Teague, J.W., 1969. Marihuana psychosis. Acute toxic psychosis associated with the use of cannabis derivatives. *JAMA* 210, 299–302.
- Tennant Jr., F.S., Groesbeck, C.J., 1972. Psychiatric effects of hashish. *Arch. Gen. Psychiatry* 27, 133–136.
- Thacore, V.R., 1973. Bhang psychosis. *Br. J. Psychiatry* 123, 225–229.
- Thaker, G.K., 2008. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. *Schizophr. Bull.* 34, 760–773.
- Tinklenberg, J.R., Kopell, B.S., Melges, F.T., Hollister, L.E., 1972. Marihuana and alcohol, time production and memory functions. *Arch. Gen. Psychiatry* 27, 812–815.
- Turetsky, B.I., Calkins, M.E., Light, G.A., Olincy, A., Radant, A.D., Swerdlow, N.R., 2007. Neurophysiological endophenotypes of schizophrenia : the viability of selected candidate measures. *Schizophr. Bull.* 33, 69–94.
- Tzilos, G.K., Cintron, C.B., Wood, J.B., Simpson, N.S., Young, A.D., Pope Jr., H.G., Yurgelun-Todd, D.A., 2005. Lack of hippocampal volume change in long-term heavy cannabis users. *Am. J. Addict.* 14, 64–72.
- Valjent, E., Pages, C., Rogard, M., Besson, M.J., Maldonado, R., Caboche, J., 2001. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. *Eur. J. Neurosci.* 14, 342–352.
- Van Os, J., Bak, M., Hanssen, M., Bijl, R.V., de Graaf, R., Verdoux, H., 2002. Cannabis use and psychosis : a longitudinal population-based study. *Am. J. Epidemiol.* 156, 319–327.
- Wang, X., Dow-Edwards, D., Anderson, V., Minkoff, H., Hurd, Y.L., 2004. In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. *Biol. Psychiatry* 56, 909–915.
- Watson, S., Chambers, D., Hobbs, C., Doherty, P., Graham, A., 2008. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. *Mol. Cell. Neurosci.* 38, 89–97.
- Weinberger, D.R., 1996. On the plausibility of “the neurodevelopmental hypothesis” of schizophrenia. *Neuropsychopharmacology* 14, 15–11S.
- Williams, E.H., Himmelsbach, C.K., Lloyd, B.J., Ruble, D.C., Wikler, A., 1946. Studies on marihuana and parahexyl compound. *Public Health Rep.* 61, 1059–1083.

Wilson, R.I., Nicoll, R.A., 2002. Endocannabinoid signaling in the brain. *Science* 296, 678–682.

Wilson, W., Mathew, R., Turkington, T., Hawk, T., Coleman, R.E., Provenzale, J., 2000. Brain morphological changes and early marijuana use : a magnetic resonance and positron emission tomography study. *J.Addict.*

Dis. 19, 1–22. Wobrock, T., Sittinger, H., Behrendt, B., D'Amelio, R., Falkai, P., 2009. Comorbid substance abuse and brain morphology in recent-onset psychosis. *Eur.*

Retrouvez Éduscol sur

